How to perform fast and accurate 3D ligand-based affinity predictions
Binding affinity prediction continues to be a challenge in computer-aided drug design, especially in the absence of a high-quality target…
In this webinar, join Matt Segall as he demonstrates how Cerella™ (AI drug discovery software) highlights new opportunities and guides more efficient compound optimisation. The webinar will show case how you can:
- Translate AI insights into the planning of experiments
- Increase confidence in decision making and lead optimisation
- Gain more value from your compound data
We will demonstrate how Cerella™ can bring these benefits to your projects, intuitively and interactively, based on your latest data. We’ll introduce the unique Alchemite™ method for deep learning imputation that powers Cerella.
Meet the speakers
Matthew Segall
CEO, Optibrium
Matt has a Master of Science in Computation from the University of Oxford and a PhD in Theoretical Physics from the University of Cambridge. As Associate Director at Camitro (UK), ArQule Inc. and then Inpharmatica, he led a team developing predictive ADME models and state-of-the-art intuitive decision-support and visualization tools for drug discovery. In January 2006, he became responsible for management of Inpharmatica’s ADME business, including experimental ADME services and the StarDrop software platform. Following acquisition of Inpharmatica, Matt became Senior Director responsible for BioFocus DPI’s ADMET division and in 2009 led a management buyout of the StarDrop business to found Optibrium.
Other webinars you may be interested in
Computational and experimental integration in modern cancer drug discovery: The synthetic lethality approach
Join us for a webinar featuring experts from IDEAYA Biosciences and CDD Vault as they explore how synthetic lethality is…
